Overview of Lasonil

Quick Facts

Property	Description
Active ingredient	Danaparoid Sodium
Form	Solution for injection
Pharmacological class	Anticoagulant, Heparinoid, Antithrombotic
General Purpose	Prevention and management of unwanted blood clots
Origin	Derived from porcine intestinal mucosa

Lasonil: Definition, Type, and Class

Lasonil, specifically in its formulation containing Danaparoid, is a prescription Anticoagulant medicine. Its single active component, Danaparoid Sodium, is formally classified as a Heparinoid. This classification is clinically recognized for identifying drugs that are structurally similar to heparin yet possess specific functional characteristics that differentiate them within the Anticoagulant class.

As an Antithrombotic distinct from traditional heparins, Danaparoid exhibits a significantly lower potential for cross-reactivity with certain antibodies associated with specific, severe clotting disorders. This unique composition provides a specialized option for patients who require ongoing clotting management but cannot tolerate other common anticoagulants.

Composition, Origin, and Pharmaceutical Form

Danaparoid Sodium is a complex mixture of highly sulfated Glycosaminoglycans, including Heparan Sulfate, Dermatan Sulfate, and Chondroitin Sulfate. The active substance is derived from purified raw material sourced from porcine intestinal mucosa.

Lasonil is supplied exclusively as a sterile Solution for injection and is administered via the parenteral route, specifically the subcutaneous route or the intravenous route. The injectable form ensures rapid and predictable systemic delivery, which is essential for achieving immediate and sustained antithrombotic effectiveness in adult patients.

The General Purpose of This Antithrombotic

Its fundamental purpose is to prevent the formation of unwanted blood clots, or thrombi, by exerting a potent Antithrombotic potential. It achieves this by primarily enhancing the body's natural anticoagulant protein, Antithrombin III. This mechanism allows it to strategically inhibit Activated Factor X (Factor Xa), a pivotal enzyme in the clotting cascade. By interrupting this critical step, the medicine helps maintain essential blood fluidity; for example, it is typically used to manage blood flow in high-risk patients.

What side effects are possible with Lasonil?

Possible Side Effects and Safety Information

The safety profile for Lasonil is predominantly characterized by local reactions at the application site and the potential for generalized hypersensitivity reactions.

Adverse Reactions

Adverse reactions are classified based on official frequency definitions (e.g., Very Common, Common, Uncommon, Rare, Very Rare, Not Known) as defined by regulatory bodies like the EMA and are typically categorized by the System Organ Class involved. For Lasonil, the primary system affected is the Skin and subcutaneous tissue disorders.

System Organ Class	Typical Adverse Reactions
Skin and Subcutaneous Tissue Disorders	Localized skin reactions such as redness (erythema), burning sensation, irritation, itching (pruritus), and contact dermatitis.
Immune System Disorders	Hypersensitivity reactions, including urticaria (hives) or angioedema (swelling).

Clinically Significant and Serious Reactions

While topical products are generally associated with low systemic exposure, serious adverse reactions can occur, particularly those related to the immune system. These may include severe, generalized hypersensitivity reactions such as anaphylaxis (a rapid, life-threatening allergic reaction), Stevens-Johnson Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN). Such severe cutaneous reactions are considered very rare but require immediate cessation of use if suspected.

Safety Restrictions and Monitoring

Lasonil is contraindicated in individuals with known hypersensitivity to its active substance or any of its excipients. Regulatory documents advise against applying the product to open wounds, damaged skin, or mucous membranes, as this may increase the rate and extent of systemic absorption, potentially raising the risk of systemic adverse effects. Treatment must be discontinued upon the first sign of a generalized rash or other hypersensitivity symptoms.

This safety information establishes that the risks are chiefly local and mild, but underscores the importance of being aware of rare, serious systemic reactions, particularly for individuals with pre-existing sensitivities.

Overdose and Emergency Response

The most prominent officially documented manifestation of accidental overdosage with Danaparoid Sodium (Lasonil) is the potential for severe, life-threatening bleeding complications (hemorrhage). This risk is a direct consequence of the drug's antithrombotic activity, as noted in regulatory labeling.

When to Seek Immediate Medical Help

Any sign or symptom suggesting severe bleeding necessitates immediate medical attention. Regulatory authorities mandate that emergency medical care be sought without delay if overdosage is suspected. The medicine must be promptly discontinued upon recognition of serious bleeding complications. Urgent diagnosis and treatment are also required if severe symptoms of neurological compromise, such as a spinal or epidural hematoma, are suspected.

Management and Antidote Status

Official regulatory information states that there is no specific antidote known to completely reverse the effects of Danaparoid Sodium. While Protamine sulfate may partially neutralize the anti-clotting Factor Xa activity, there is no documented evidence confirming its ability to reduce severe non-surgical bleeding resulting from overdosage. Management of overdosage is therefore primarily symptomatic and supportive, which may include the use of blood transfusions if deemed necessary to stabilize the patient's condition. A critical population consideration is that patients with severe renal impairment face an increased risk of accumulation, prolonging the half-life and raising the potential for overdosage.

Therapeutic Uses of Lasonil

Lasonil's therapeutic domain is applied across areas where short-term symptomatic support is needed for conditions presenting with localized discomfort, specifically those that involve inflammatory or irritative processes beneath the skin. The main active component, Mucopolysaccharide Polysulfate (MPS) or a related heparinoid, is used for managing several symptoms associated with blunt injury.

The preparation is relevant for easing symptoms of superficial bruising (haematoma) and is commonly used for superficial thrombophlebitis, a condition where functional stability becomes affected due to inflammation of a vein just below the surface. This therapeutic domain is relevant in contexts involving heightened systemic burden, helping address symptom clusters that may become intense or disruptive following a trauma.

This symptomatic assistance helps ease the overall symptom burden and may assist with maintaining functional stability during episodes of heightened discomfort.

“The preparation is relevant for easing superficial bruising and haematoma.”

Quick Fact: Supports general well-being during symptomatic phases

Regulatory References

Malta Medicines Authority SPC for Hirudoid Gel

Eligibility and Restrictions for Use

Who Can and Cannot Use Lasonil?

Lasonil (Danaparoid Sodium) is an anticoagulant medicine whose eligibility is defined strictly by official government regulatory labels. Established use is primarily limited to adult patients for specific antithrombotic needs, such as managing Heparin-Induced Thrombocytopenia (HIT) or for deep vein thrombosis (DVT) prophylaxis in specific surgical settings.

Use is Strictly Contraindicated

The medicine must not be used in patients with the following absolute prohibitions, as specified in regulatory documentation:

Known hypersensitivity to Danaparoid Sodium or any component, including sulphite.
An active, uncontrolled bleeding state or severe hemorrhagic diathesis.
Severe kidney or liver disorders.
Acute hemorrhagic stroke, severe untreated hypertension, or diabetic retinopathy.
Active gastric or duodenal ulcers, unless required for an operative procedure.

Restricted and Conditional Use

Certain populations require special consideration or restriction:

Organ Function: Patients with moderate renal or hepatic impairment must be treated with caution and close monitoring due to the potential for altered drug activity.
Pregnancy and Lactation: Use during pregnancy is not generally recommended and is conditional upon the physician determining the therapeutic benefits outweigh potential risks. Breastfeeding mothers are generally advised to avoid use.
Age: Use in children and adolescents is possible but subject to a physician's determination due to limited clinical experience. Additionally, the drug should not be used to prevent blood clots in patients with prosthetic heart valves due to insufficient supporting data.

What should I know about interactions with other medicines?

Lasonil Interactions with other medicines and products

The interaction profile for Lasonil is formally defined by the regulatory documents covering its two distinct active substances: Danaparoid Sodium for systemic injection and Mucopolysaccharide Polysulfate for topical application. The following information strictly reflects the findings published by health authorities.

A. Danaparoid Sodium (Systemic Anticoagulant)

Official regulatory documents focus on pharmacodynamic interactions that affect the hemostasis system, resulting in an increased risk of hemorrhage.

Interaction Category	Interacting Agents	Official Regulatory Statement
Pharmacodynamic Risk	Oral Anticoagulants	Co-administration increases the documented risk of hemorrhage.
Pharmacodynamic Risk	Platelet Inhibitors (including NSAIDs and Acetylsalicylic acid)	Co-administration increases the risk of bleeding. Caution is required when neuraxial anesthesia is employed due to the risk of spinal or epidural hematoma.

The labeling incorporates procedural and population constraints. A timing rule requires that specific coagulation assays, such as Prothrombin Time (PT) and Thrombotest, are officially described as unreliable for monitoring oral anticoagulants if performed within 5 hours following Danaparoid Sodium administration. Additionally, the half-life of anti-Xa activity may be prolonged in patients with Severely Impaired Renal Function, which alters systemic exposure and requires official consideration.

B. Mucopolysaccharide Polysulfate (Topical Heparinoid)

Regulatory documents for the topical formulation officially state that there are no known interactions with other medicinal products.

Mechanism of Action

Targeted Catalytic Suppression of the Coagulation Cascade

Danaparoid Sodium is an anticoagulant that works by binding to the endogenous anticoagulant protein, Antithrombin III (ATIII). This binding causes a crucial conformational change in ATIII, accelerating its inhibitory function on Activated Factor X (Factor Xa). Neutralizing Factor Xa interrupts the common pathway of blood coagulation before massive Thrombin generation can occur.

Mechanism-Driven Selectivity and Factor IIa Constraint

The drug's molecular structure provides a distinct mechanistic profile characterized by selectivity. Due to its specific arrangement of glycosaminoglycans, Danaparoid has low affinity for Thrombin (Factor IIa), meaning its activity is predominantly Anti-Factor Xa. This structural constraint also results in minimal interaction with Platelet Factor 4 (PF4). This selectivity shapes the resulting physiological effect as the preservation of coagulation homeostasis through selective enzyme suppression.

Dosage and Administration Information

Administration of Lasonil

Lasonil is a topical preparation designed for application directly to the skin. It is formulated to be absorbed through the cutaneous layers to reach the underlying tissues.

Application Method

The product is typically applied by spreading a thin layer over the affected area. Depending on the specific condition being addressed, the cream or ointment may be applied with gentle massage to facilitate absorption, or it may be spread lightly if the area is sensitive or bruised. In certain cases, a protective dressing or bandage may be placed over the treated area after application.

Usage Considerations

Surface Integrity: The preparation is intended for use on intact skin. Standard practice involves avoiding contact with open wounds, mucous membranes, or the eyes.
Absorption Factors: The rate of absorption can be influenced by the surface area treated and the condition of the skin barrier.
Cleanliness: It is standard procedure to ensure the skin is clean and dry before applying the topical agent. Hands are generally washed before and after the application process to maintain hygiene and prevent accidental transfer to other areas.

Recent Clinical Evidence

Lasonil: Overview of Research Evidence

Clinical evidence for Lasonil is reviewed based on the two distinct active components: Danaparoid Sodium (for systemic injectable use) and Mucopolysaccharide Polysulfate (for localized topical use).

Evidence for Systemic Use (Danaparoid Sodium)

Heparin-Induced Thrombocytopenia (HIT): Research exploring the use of Danaparoid in the context of HIT has relied primarily on retrospective analyses, case series, and older non-randomized studies. Researchers monitored outcomes related to systemic imbalance, such as platelet count measurements and the frequency of thrombotic events observed during study periods. Long-term effects and modern comparative evidence against newer anticoagulant alternatives are not fully established.

Deep Vein Thrombosis (DVT) Prophylaxis: Historical Randomized Controlled Trials (RCTs) evaluated DVT prevention in surgical adults, monitoring the incidence of confirmed DVT and Pulmonary Embolism (PE). Studies described patterns related to the study's prophylactic objective compared to certain older treatments. Comparative evidence against current standard-of-care therapies (like LMWHs or DOACs) is lacking, limiting the applicability of results to older treatment environments.

Evidence for Topical Use (Mucopolysaccharide Polysulfate)

Superficial Bruising and Injury: Placebo-Controlled Double-Blind Trials evaluated the topical preparation. Research monitored outcomes related to physical discomfort and highlighted differences in the measured time to absorption of induced haematomas between the active preparation and placebo. Follow-up durations were limited to the short-term time until local resolution.

Superficial Thrombophlebitis: Studies monitored outcomes linked to inflammatory states, such as local pain and the rate of lesion regression, in the context of this acute condition. Findings indicate patterns related to outcomes of physical discomfort measured during the brief study period. Evidence quality varies, and there is limited information on its role in relation to modern systemic treatments.

Research Gaps and Special Populations

Studies for the injectable formulation monitored its use in adults with renal impairment, where the concentration of the medicine may be prolonged due to its elimination route. Data for children and pregnancy-related populations remain insufficient. A primary uncertainty across the systemic indications is the lack of large, modern RCTs comparing Danaparoid to the newest anticoagulants.

Key Studies & References Topical mucopolysaccharide polysulfate (MPS) in the treatment of thrombophlebitis – A critical review

Frequently Asked Questions (FAQ)

Common questions about Lasonil (FAQ)

Q: Is Lasonil a prescription medicine or over-the-counter?

A: According to official regulatory classifications, the topical formulation of Lasonil containing Mucopolysaccharide Polysulfate is generally classified as an Over-The-Counter (OTC) medicine in many regulated markets. This classification means it can be purchased without a doctor's prescription.

Q: Does Lasonil help with swelling?

A: Official product information indicates that Lasonil is used to relieve pain and stiffness and possesses anti-exudatory activity (activity that helps reduce fluid build-up or swelling). This effect is supported by its official indications.

Q: Why do people use Lasonil for bruises?

A: Official documents state that Lasonil is indicated for the treatment of bruises and conditions associated with the inflammation of superficial veins. Research has examined its use in reducing the time required for haematomas, or collections of clotted blood under the skin, to be absorbed.

Q: What happens if I accidentally put Lasonil on broken skin?

A: Official safety documents state that the product is contraindicated for use on broken or sensitive skin and on mucous membranes. This warning is in place because application to damaged skin may increase the rate and extent of the medicine's systemic absorption.

Q: Is it possible to be allergic to Lasonil?

A: Official product information notes that Lasonil is contraindicated in patients with a known hypersensitivity (allergic reaction) to the active substance or any of its inactive components. Additionally, caution is advised for people with known allergies to aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs).

Q: Is Lasonil applied only once a day?

A: Official product instructions state that the medicine may be applied to the affected area multiple times daily for those over 12 years of age. This frequency is higher than a single daily application.

Q: Can Lasonil be used long-term?

A: Official safety guidance suggests that Lasonil is generally safe for short-term use. If a condition requires prolonged or continuous use, official guidance suggests that this should occur under the monitoring of a healthcare professional.

Q: Does Lasonil absorb deeply into the muscle?

A: Systemic absorption is minimal, as pharmacokinetic studies indicate the substance primarily binds within the subcutis (the tissue layer beneath the skin). This suggests the medication is intended for localized action.

Q: Is there a risk of Lasonil entering the bloodstream?

A: A small amount of the active substance may be absorbed into the body after topical application. However, regulatory documents state that the peak concentrations found in the blood are below the level required to physiologically affect the clotting system.

Q: Do official patient leaflets mention specific skin reactions?

A: Yes, official product information advises users to discontinue use if excessive irritation or other unwanted local effects occur. Common skin reactions often listed include redness (erythema), a burning sensation, irritation, and itching (pruritus).

Q: Is Lasonil used for muscle pain?

A: Official regulatory indications for the topical product list its use for the symptomatic relief of muscular pain and stiffness. It is also indicated for sprains and strains.

Q: How quickly does Lasonil start working after application?

A: The regulatory documents do not specify a precise clinical onset of action for the pain-relieving effects. However, research into its related effects on skin hydration has shown that positive changes can be maintained for up to 10 hours after a single application.

Q: How long do the effects of Lasonil typically last?

A: The duration of the full therapeutic effect is not strictly defined in official documents. Related studies, however, suggest that specific effects, such as improved skin hydration, can be sustained for at least 10 hours after the product has been applied once.

Q: Is Lasonil safe to use on skin that is already irritated?

A: Official product information indicates that Lasonil is contraindicated for use on sensitive skin. Users are advised to discontinue use if excessive irritation occurs.

Q: Is Lasonil appropriate for older adults (the elderly)?

A: The official administration instructions state that the same application methods specified for adults include the elderly. Therefore, no separate dosage adjustments are typically required based solely on advanced age.

Q: Is Lasonil considered a type of anti-inflammatory medicine?

A: Lasonil is officially classified as a non-steroidal drug with confirmed anti-inflammatory activity. Official documents describe this effect as being due to a weak inhibitory action on certain inflammation-causing substances within the body.

Q: What are the most common side effects listed for Lasonil?

A: Official adverse event information states that common side effects are generally localized to the application site. These typically include localized reactions such as redness (erythema), a burning sensation, irritation, and itching (pruritus).

Q: Is a slight stinging sensation normal when I first apply Lasonil?

A: Official adverse event listings for this type of topical medicine indicate that a stinging or burning sensation at the application site is a possible local reaction. Users who experience excessive or persistent discomfort should discontinue use.

Q: Can Lasonil interact with supplements like vitamins or herbs?

A: While specific supplement interactions may not be listed, general safety warnings advise that a healthcare professional should be informed of all medicines, herbs, and supplements being used. This practice helps ensure the safe use of the product.

Q: Is Lasonil suitable for sports injuries?

A: The product’s official indications include symptomatic relief for sprains and strains, making it relevant for some common, non-serious sports injuries. It helps with the pain and stiffness often associated with these minor injuries.

Q: Why is Lasonil sometimes recommended for reducing the appearance of scars?

A: Lasonil is officially indicated in the treatment of specific abnormal scars, including hypertrophic scars and keloids. This use relates to its ability to promote skin hydration and elasticity.

Q: Is Lasonil a steroid?

A: Lasonil is officially classified as a non-steroidal drug with anti-coagulant and anti-inflammatory properties, and is not categorized as a corticosteroid.

Q: Are there any restrictions on combining Lasonil with heat or ice packs?

A: Official product information contains a specific safety warning advising patients not to smoke or go near naked flames. This warning is due to a fire hazard risk, as fabric (such as clothing or dressings) that has been in contact with the product can be flammable.

Q: Is there a specific mechanism described for how Lasonil helps with inflammation?

A: Official documents describe that the product's anti-inflammatory activity is due to a weak inhibitory effect of PGE2 synthesis (PGE2 is a compound involved in inflammation). This is the stated mechanism for its anti-inflammatory properties.

Q: Do official sources discuss potential long-term skin thinning with Lasonil use?

A: Official warnings advise against applying the product to large areas of skin and recommend discontinuing use if excessive irritation occurs. Potential long-term skin changes are not generally detailed in the product label.

Q: What are the official authorized uses of Lasonil?

A: The official authorized uses of the topical formulation include the symptomatic relief of muscular pain and stiffness, sprains/strains, pain due to rheumatic/non-serious arthritic conditions, bruises, superficial thrombophlebitis, and scar reduction for hypertrophic scars and keloids.

Q: Can Lasonil be applied to sensitive areas of the body?

A: Official safety documents indicate that the product is contraindicated for use on sensitive skin and should not be applied to mucous membranes. Additionally, it is specifically advised not to use the product on the breast area during lactation.

Q: Is Lasonil effective for chronic conditions or only acute problems?

A: Official indications suggest applicability beyond only acute problems, as the product is indicated for pain associated with chronic inflammatory diseases and rheumatic conditions.

Q: Are there any known drug-disease interactions mentioned for Lasonil?

A: Official warnings advise caution in patients suffering from asthma, as adverse effects may occur. Additionally, the product is contraindicated in patients with known hypersensitivity to aspirin or other NSAIDs (Non-Steroidal Anti-inflammatory Drugs).

Q: Is Lasonil approved for use in all age groups?

A: Regulatory documents state that the use of the topical formulation is specifically contra-indicated in children under 12 years of age.

Q: Is there a maximum number of days Lasonil should be used continuously?

A: While a specific, mandated maximum duration is not consistently defined, official safety guidance confirms that the product is generally intended for short-term use. Prolonged use should be managed under the supervision of a healthcare professional.

How should Lasonil be stored and disposed of?

How to Store and Dispose of Lasonil?

Regulatory documents define specific storage and disposal requirements for both forms of Lasonil. The Danaparoid Sodium Injection must be stored at 20 C to 25 C and protected from freezing. The Topical Gel/Cream must be stored below 25 C and includes an explicit fire hazard warning, requiring users to avoid naked flames during handling.

Child Safety and Disposal

All Lasonil products must be kept out of the sight and reach of children.

Unused or expired medicine must not be discarded via household waste or poured down a drain. Instead, it must be returned to a pharmacist or a designated collection point for safe disposal, in accordance with local pharmaceutical waste regulations.

Lasonil